The Koch Institute is outward looking. Industry outreach can take various forms, including collaborations with pharma companies (both institute-wide and one-offs), licensing deals with pharma/biotech, and maximizing impact through start up companies.
A long-term partnership with Janssen Pharmaceuticals, Inc fosters oncology research and technology development in cancer diagnostics (predictive biomarkers, surrogate endpoints, and CTCs), novel therapeutic targets, drug delivery systems, cancer immunotherapies, and murine disease models to study pre-malignancies, tumor progression, and target validation.
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
500 Main Street, Building 76
Cambridge MA, 02139-4307
617-253-6403